BioScience Trends
Online ISSN : 1881-7823
Print ISSN : 1881-7815
ISSN-L : 1881-7815
Brief Reports
Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation
Yuki Oya, Yasuhiko Sugawara, Takehisa Watanabe, Yoko Yoshimaru, Masaki Honda, Shintaro Hashimoto, Daiki Yoshii, Kaori Isono, Shintaro Hayashida, Hidekazu Yamamoto, Motohiko Tanaka, Yutaka Sasaki, Yukihiro Inomata
Author information
Keywords: Liver transplantation, living donor, hepatocellular carcinoma
JOURNAL FREE ACCESS

2016 Volume 10 Issue 6 Pages 496-499

Browse “Advance online publication” version
Details
Download PDF (252K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract

Management of recurrent hepatitis C following liver transplantation still remains a challenge. Here, we report five patients who achieved viral responses following combined treatment with ledipasvir and sofosbuvir. All the patients received tacrolimus for immunosuppression. No dose adjustment was made before the ledipasvir and sofosbuvir therapy. All completed the intended 12-week treatment course with the full dose of ledipasvir and sofosbuvir. There were no significant adverse events greater than grade 2. During the study period, no acute rejection episodes were detected. The trough levels of tacrolimus were maintained stably. Hepatitis C virus RNA was not detected at week 12 in any of the patients. Based on the findings from this pilot study, combined ledipasvir and sofosbuvir therapy for 12 weeks is effective and safe for living - donor liver transplantation recipients with recurrence of hepatitis C virus.

Content from these authors
© 2016 International Research and Cooperation Association for Bio & Socio-Sciences Advancement
Previous article Next article
Favorites & Alerts

Recently viewed articles
Share this page
feedback
 Top